JP Morgan Chase
PETX

JP Morgan Chase’s Aratana Therapeutics, Inc. PETX Stock Holding History

JP Morgan Chase’s Portfolio PETX Stock Details PETX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-13,287
Closed -$68K – 6144
2019
Q2 		$68K Buy
13,287
+1,978
+17% +$8.89K ﹤0.01% 5061
2019
Q1 		$41K Sell
11,309
-39,116
-78% -$170K ﹤0.01% 5204
2018
Q4 		$310K Buy
50,425
+39,899
+379% +$243K ﹤0.01% 4374
2018
Q3 		$61K Sell
10,526
-50,955
-83% -$255K ﹤0.01% 5131
2018
Q2 		$262K Buy
61,481
+53,147
+638% +$268K ﹤0.01% 4454
2018
Q1 		$37K Sell
8,334
-1,242
-13% -$5.54K ﹤0.01% 4914
2017
Q4 		$50K Buy
9,576
+9,448
+7,381% +$57.8K ﹤0.01% 4902
2017
Q3 		$1K Buy
+128
New +$810 ﹤0.01% 4933
2017
Q1 		– Sell
-19,958
Closed -$143K – 5340
2016
Q4 		$143K Buy
+19,958
New +$161K ﹤0.01% 4284
2016
Q3 		– Sell
-3,663
Closed -$23K – 4962
2016
Q2 		$23K Sell
3,663
-104
-3% -$669 ﹤0.01% 4205
2016
Q1 		$21K Buy
+3,767
New +$14.2K ﹤0.01% 4077
2015
Q1 		– Sell
-333,616
Closed -$5.95M – 4378
2014
Q4 		$5.95M Sell
333,616
-252,927
-43% -$3.15M ﹤0.01% 2300
2014
Q3 		$5.89M Sell
586,543
-47,128
-7% -$571K ﹤0.01% 2255
2014
Q2 		$9.89M Sell
633,671
-110,979
-15% -$1.57M ﹤0.01% 1751
2014
Q1 		$13.8M Sell
744,650
-12,187
-2% -$244K ﹤0.01% 1545
2013
Q4 		$14.5M Buy
756,837
+304,144
+67% +$6.17M ﹤0.01% 1548
2013
Q3 		$7.4M Sell
452,693
-273,507
-38% -$2.87M ﹤0.01% 1942
2013
Q2 		$5.49M Buy
+726,200
New +$5.74M ﹤0.01% 2077

Other funds holding PETX

DC
Davenport & Co Richmond, Virginia $20.4B AUM 18.11% 1-Year Est. Return
ASN
Advisory Services Network Atlanta, Georgia $7.52B AUM 29.01% 1-Year Est. Return

JP Morgan Chase's PETX Position: Q3 2019 in Review

JP Morgan Chase sold out of Aratana Therapeutics, Inc. (PETX) in Q3 2019, closing a stake of 13,287 shares — an estimated $68K sold.

JP Morgan Chase first reported a position in PETX in Q2 2013 and held it in 18 quarters. The position peaked at $14.5M in Q4 2013. 2 funds tracked by Wall St. Rank hold PETX as of Q3 2019.

  • JP Morgan Chase reported no remaining Aratana Therapeutics, Inc. position as of Q3 2019 after selling out during the quarter.
  • JP Morgan Chase sold 13,287 Aratana Therapeutics, Inc. shares in Q3 2019, an estimated $68K.
  • JP Morgan Chase first reported a position in Aratana Therapeutics, Inc. in Q2 2013 and held it in 18 quarters.
  • JP Morgan Chase's Aratana Therapeutics, Inc. position peaked at $14.5M in Q4 2013.
  • 2 funds tracked by Wall St. Rank held Aratana Therapeutics, Inc. as of Q3 2019.

Based on JP Morgan Chase's 13F filing for Q3 2019, filed 12 Nov 2019.